NEW YORK – Scipher Medicine said on Wednesday that it has completed a second close in its previously announced Series B financing round, raising its total to $25 million with a new investment from Optum Ventures.
Based in Waltham, Massachusetts, Scipher is developing molecular tests to aid in therapeutic decision-making in the autoimmune disease space, using a proprietary approach for discovering RNA signatures. The first of these assays is PrismRA, a test to predict response to anti-tumor necrosis (anti-TNF) therapies in rheumatoid arthritis patients.
According to the company, Optum Ventures' investment, along with other Series B investments, will help accelerate its work on PrismRA and further its expansion into other difficult-to-treat and complex disease areas.